Use of bone marrow derived mesenchymal stem cells for the treatment of osteoarthritis: A retrospective long-term follow-up study

Mariani, Cesare; Meneghetti, Ezio; Zambon, Doriano; Elena, Nicholas; Agueci, Alberto; Melchior, Claudio

doi:10.1016/j.jcot.2022.102084

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, both have been discussed as types of “stem cell” therapy. 19 , 21 , 26 Over time, this has been clarified, as the population of mesenchymal stem cells is minute and unlikely to be the primary source of treatment effect. 8 The emphasis on these interventions then shifted from stem cells to proteins like interleukin-1 receptor antagonist protein in BMAC and macrophage density in adipose tissue.…”

Section: Discussionmentioning

confidence: 99%

Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial

Baria,

Barker,

Durgam

et al. 2024

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

Background: Platelet-rich plasma (PRP) is an effective treatment for knee osteoarthritis (OA). Microfragmented adipose tissue (MFAT) is another orthobiologic that holds promise, but data supporting its use are limited. Previous studies showed that MFAT created using the Lipogems device was equivalent to PRP created via noncommercial laboratory-based processes. Purpose: To perform a comparison of commercially available MFAT and PRP systems for treatment of knee OA. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: A total of 71 patients with symptomatic knee OA (Kellgren-Lawrence grades 1-4) were randomized to receive a single injection of either leukocyte-rich PRP (Angel; Arthrex) or MFAT (Lipogems) under ultrasound guidance. Patient-reported outcomes (Knee injury and Osteoarthritis Outcome Score [KOOS], visual analog scale for pain with activities of daily living [VAS pain], and Tegner activity level) were recorded at baseline and at 1, 3, 6, and 12 months after injection. The primary outcome was the KOOS-Pain subscale score at 12 months after injection. Results: Overall, 49 patients completed their 12-month follow-up (PRP group, n = 23; MFAT group, n = 26). All demographic features were similar between groups, except that more men were randomized to the PRP group and more women to the MFAT group. At 12 months posttreatment, KOOS-Pain scores improved in both groups, with no significant group difference (PRP, 78 ± 17.9 vs MFAT, 77.8 ± 19.3; P = .69). Similarly, other KOOS subscales, VAS pain scores, and Tegner scores improved at 12 months, with no differences between treatment groups. Conclusion: Both PRP and MFAT injections for knee OA resulted in improved patient-reported outcomes at 12 months posttreatment, with no differences found between treatments. Registration: NCT04351087 (ClinicalTrials.gov identifier).

show abstract

Section: Discussionmentioning

confidence: 99%

Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial

Baria,

Barker,

Durgam

et al. 2024

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

show abstract

“…They found that the PRP group had a significantly lower failure rate, as well as statistically significant improvements on the VAS and KOOS scales compared to those of the non-PRP group [70]. Bone marrow aspirate concentrate (BMAC) also contains growth factors, such as PGF, TGF-β, and BMP2-7, which also provide anti-inflammatory and healing effects to the damaged meniscus [71]. Massey et al treated patients with BMAC after arthroscopic meniscus repair.…”

Section: Discussionmentioning

confidence: 99%

“…Mariani et al demonstrated an improvement in osteoarthritis symptoms with a single injection of BMAC. The Tegner, VAS and WOMAC scores improved in all the groups according to Kellgren-Laurence (grades 1, 2, and 3) [71]. Fokter et al investigated the injection of an engineered calcium phosphate compound in a 76-year-old woman.…”

Section: Discussionmentioning

confidence: 99%

Molecular Biology of Meniscal Healing: A Narrative Review

Tramś,

Kamiński

2024

IJMS

View full text Add to dashboard Cite

This review provides insights at the molecular level into the current and old methods for treating meniscal injuries. Meniscal injuries have been found to have a substantial impact on the progression of osteoarthritis. In line with the “save the meniscus” approach, meniscectomy is considered a last-resort treatment. Nevertheless, it is important to note that mechanical repair alone may not achieve the complete restoration of the meniscus. A deep understanding of the healing pathways could lead to future improvements in meniscal healing. The inclusion of cytokines and chemokines has the potential to facilitate the process of tear repair or impede the inflammatory catabolic cascade. MicroRNA (miRNA) could serve as a potential biomarker for meniscal degeneration, and RNA injections might promote collagen and growth factor production. The critical aspect of the healing process is angiogenesis within the inner zone of the meniscus. The use of collagen scaffolds and the implantation of autologous meniscus fragments have been successfully integrated into clinical settings. These findings are encouraging and underscore the need for well-designed clinical trials to explore the most effective factors that can enhance the process of meniscal repair.

show abstract

“…Mesenchymal stem cells from bone marrow, appear to have low contributor incidence and can harvest easily, making them potential candidates for healing major bone cracks among the plentiful sources [15][16][17]. Importantly, hBMSCs are utilized to treat a range of ailments, including bone deformities, osteoarthritis, and arthritic, while also possessing the potential to alter bone homeostasis [18][19][20]. However, the osteogenic potential of hBMSCs in bone healing remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Nonthermal biocompatible plasma in stimulating osteogenic differentiation by targeting p38/ FOXO1 and PI3K/AKT pathways in hBMSCs

Akter,

Kim,

Choi

et al. 2024

J Biol Eng

View full text Add to dashboard Cite

Osteoporosis is manifested by decreased bone density and deterioration of bone architecture, increasing the risk of bone fractures Human bone marrow mesenchymal stem cells (hBMSCs)-based tissue engineering serves as a crucial technique for regenerating lost bone and preventing osteoporosis. Non-thermal biocompatible plasma (NBP) is a potential new therapeutic approach employed in several biomedical applications, including regenerative medicine. NBP affects bone remodeling; however, its role in the regulation of osteogenic differentiation in hBMSCs remains largely unexplored. This study aimed to explore the efficiency of NBP in promoting osteogenic differentiation, and the molecular pathways through which these responses occurred in hBMSCs. We found that NBP facilitated osteogenic differentiation through the upregulation of the bone morphogenic protein signal (BMPs) cascade, which in turn induced the expression of p38 and inhibited the forkhead box protein O1 (FOXO1). To further gain insight into the mechanism through which NBP extensively triggers the initiation of osteogenic differentiation in hBMSCs, PI3K/AKT pathway was also analyzed. Overall, these results highlight that NBP enhances osteogenic differentiation in hBMSCs by the stimulation of the p38/FOXO1 through PI3K/AKT signaling pathways. Therefore, the application of NBP in hBMSCs may offer tremendous therapeutic prospects in the treatment of bone regeneration and osteoporosis prevention.

show abstract

Use of bone marrow derived mesenchymal stem cells for the treatment of osteoarthritis: A retrospective long-term follow-up study

Cited by 5 publications

References 32 publications

Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial

Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial

Molecular Biology of Meniscal Healing: A Narrative Review

Nonthermal biocompatible plasma in stimulating osteogenic differentiation by targeting p38/ FOXO1 and PI3K/AKT pathways in hBMSCs

Contact Info

Product

Resources

About